Oncology · Surgery · 5 h ago
Liver-first interval length was not linked to survival in colorectal liver metastases
A commentary discusses a retrospective LiverMetSurvey analysis of 739 patients treated with a liver-first approach for synchronous colorectal liver metastases. The analysis found no overall-survival difference across three intervals between liver and colorectal surgery; systemic therapy during the interval was associated with better survival.
- Interval length was not associated with overall survival.
- Systemic therapy during the interval correlated with better survival.
- Interval recurrence occurred in 7.6% of patients.
- Resectable recurrence did not preclude comparable survival.
For patients with synchronous colorectal liver metastases, the sequence and timing of liver and primary-tumor surgery are individualized. This commentary reviews a retrospective analysis of the prospective international LiverMetSurvey registry, which included 739 liver-first patients among 16,324 hepatectomies recorded from 2000 to 2023. The analysis examined the interval between liver and colorectal resection, interval systemic therapy, and recurrence before colorectal surgery.
Overall survival did not differ significantly among patients whose interval was shorter than 3 months, 3–6 months, or longer than 6 months. Systemic therapy during the interval was independently associated with improved 5-year overall survival, although the source gives no absolute survival estimates. Recurrence during the interval occurred in 7.6% of patients. Those with recurrence that could be resected had survival comparable to patients without interval recurrence.
The findings suggest that a longer interval need not, by itself, prompt earlier colorectal surgery, and that selected patients with resectable recurrence may still proceed with curative-intent treatment. However, the registry analysis was retrospective: the chemotherapy association does not establish a causal benefit, and the results do not determine an optimal regimen or timing. The commentary calls for prospective studies of treatment during this interval.
In practice
For patients selected for a liver-first approach to synchronous colorectal liver metastases, this registry analysis found no overall-survival difference across intervals of less than 3 months, 3–6 months, or more than 6 months before colorectal resection. This may support individualizing timing around recovery and clinical readiness rather than using an arbitrary interval threshold. The evidence is retrospective and does not establish that interval chemotherapy improves survival; it does not justify a change in treatment practice. Selected patients with resectable interval recurrence had survival comparable to those without recurrence.
AI-generated clinical interpretation · Not editor-reviewed
Is this summary clinically accurate?
Help fellow clinicians: your rating sends inaccurate summaries straight to our editors.
Sign in to rate this summary →Source
Annals of Surgical Oncology: Mind the Gap: The Liver-first Approach to Synchronous Colorectal Liver Metastases and Optimization of the Interval Between Liver and Colorectal Resection ↗This is an automated AI-condensed summary that has not yet been reviewed by an editor. Always consult the full item at the original source.